LAVAL, Dec. 13 /CNW Telbec/ - LAB International Inc. (TSX: LAB,
Frankfurt: LD9.F, XETRA: LD9.DE) ("LAB"), an integrated drug development
company with subsidiaries focused on developing therapies for the inhalation
market and on providing contract research services, today announced that it
has raised $12.3 million through the non-brokered private placement of
13 996 466 common shares at a price of $0.88 per share.
